CDC-Authored Genomics and Precision Health Publications Database
Last data update: Jan 15, 2021. (Total: 3111 publications since 2011)
| Query Trace: all>>James E Posey[CDC Author] |
|---|
| Molecular evaluation of fluoroquinolone resistance in serial Mycobacterium tuberculosis isolates from individuals diagnosed with multidrug-resistant tuberculosis. Melisa Willby, Paige Chopra, Darrin Lemmer, Katherine Klein, Tracy L Dalton, David M Engelthaler, Peter Cegielski, James E Posey, and Antimicrobial agents and chemotherapy 2020 Oct |
| Isoniazid- and Rifampin-Resistance Mutations Associated with Resistance to Second-line Drugs and with Sputum Culture Conversion. Eleanor S Click, Ekaterina Kurbatova, Heather Alexander, Tracy L Dalton, Michael P Chen, James E Posey, Julia J Ershova, and Peter Cegielski The Journal of infectious diseases 2020 Jan |
| Pathogen Genomics in Public Health. Gregory L Armstrong, Duncan R MacCannell, Jill Taylor, Heather A Carleton, Elizabeth B Neuhaus, Richard S Bradbury, James E Posey, and Marta Gwinn The New England journal of medicine 2019 Dec (26) 2569-2580 |
| Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. , Caroline Allix-Béguec, Irena Arandjelovic, Lijun Bi, Patrick Beckert, Maryline Bonnet, Phelim Bradley, Andrea M Cabibbe, Irving Cancino-Muñoz, Mark J Caulfield, Angkana Chaiprasert, Daniela M Cirillo, David A Clifton, Iñaki Comas, Derrick W Crook, Maria R De Filippo, Han de Neeling, Roland Diel, Francis A Drobniewski, Kiatichai Faksri, Maha R Farhat, Joy Fleming, Philip Fowler, Tom A Fowler, Qian Gao, Jennifer Gardy, Deborah Gascoyne-Binzi, Ana-Luiza Gibertoni-Cruz, Ana Gil-Brusola, Tanya Golubchik, Ximena Gonzalo, Louis Grandjean, Guangxue He, Jennifer L Guthrie, Sarah Hoosdally, Martin Hunt, Zamin Iqbal, Nazir Ismail, James Johnston, Faisal M Khanzada, Chiea C Khor, Thomas A Kohl, Clare Kong, Sam Lipworth, Qingyun Liu, Gugu Maphalala, Elena Martinez, Vanessa Mathys, Matthias Merker, Paolo Miotto, Nerges Mistry, David A J Moore, Megan Murray, Stefan Niemann, Shaheed V Omar, Rick T-H Ong, Tim E A Peto, James E Posey, Therdsak Prammananan, Alexander Pym, Camilla Rodrigues, Mabel Rodrigues, Timothy Rodwell, Gian M Rossolini, Elisabeth Sánchez Padilla, Marco Schito, Xin Shen, Jay Shendure, Vitali Sintchenko, Alex Sloutsky, E Grace Smith, Matthew Snyder, Karine Soetaert, Angela M Starks, Philip Supply, Prapat Suriyapol, Sabira Tahseen, Patrick Tang, Yik-Ying Teo, Thuong N T Thuong, Guy Thwaites, Enrico Tortoli, Dick van Soolingen, A Sarah Walker, Timothy M Walker, Mark Wilcox, Daniel J Wilson, David Wyllie, Yang Yang, Hongtai Zhang, Yanlin Zhao, and Baoli Zhu The New England journal of medicine 2018 379(15) 1403-1415 |
| Validation of novel Mycobacterium tuberculosis isoniazid resistance mutations not detectable by common molecular tests. Justin L Kandler, Alexandra D Mercante, Tracy L Dalton, Matthew N Ezewudo, Lauren S Cowan, Scott P Burns, Beverly Metchock, , Peter Cegielski, and James E Posey Antimicrobial agents and chemotherapy 2018 Aug |
| Statistical Method to Detect Tuberculosis Outbreaks among Endemic Clusters in a Low-Incidence Setting. Sandy P Althomsons, Andrew N Hill, Alexia V Harrist, Anne Marie France, Krista M Powell, James E Posey, Lauren S Cowan, and Thomas R Navin Emerging infectious diseases 2018 Mar (3) 573-575 |
| Detection of Mycobacterium tuberculosis pncA mutations by the NIPRO Genoscholar(™)·PZA-TB II as compared to conventional sequencing. Melisa J Willby, Maria Wijkander, Joshua Havumaki, Kartee Johnson, Jim Werngren, Sven Hoffner, Claudia M Denkinger, and James E Posey Antimicrobial agents and chemotherapy 2017 Oct |
| Rv3351c, a Mycobacterium tuberculosis gene that affects bacterial growth and alveolar epithelial cell viability. Rebecca L Pavlicek, Kari Fine-Coulson, Tuhina Gupta, Frederick D Quinn, James E Posey, Melisa Willby, Jorge Castro-Garza, and Russell K Karls Canadian journal of microbiology 2015 Oct 1-10 |
| Mycobacterium tuberculosis pncA polymorphisms that do not confer pyrazinamide resistance at a breakpoint concentration of 100 µg/ml in MGIT. Michael G Whitfield, Robin M Warren, Elizabeth M Streicher, Samantha L Sampson, Frik A Sirgel, Paul D van Helden, Alexandra Mercante, Melisa Willby, Kelsey Hughes, Kris Birkness, Glenn Morlock, Annelies van Rie, and James E Posey J. Clin. Microbiol. 2015 Aug 19. |
| Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis. Analise Z Reeves, Patricia J Campbell, Melisa J Willby, and James E Posey Antimicrob. Agents Chemother. 2015 Jan 59(1) 444-9 |
| Antimycobacterial activity of DNA intercalator inhibitors of Mycobacterium tuberculosis primase DnaG. Chathurada Gajadeera, Melisa J Willby, Keith D Green, Pazit Shaul, Micha Fridman, Sylvie Garneau-Tsodikova, James E Posey, and Oleg V Tsodikov J. Antibiot. 2015 Mar 68(3) 153-7 |
| New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. Seidu Malik, Melisa Willby, David Sikes, Oleg V Tsodikov, and James E Posey PLoS ONE 2012 7(6) e39754 |
| Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Patricia J Campbell, Glenn P Morlock, R David Sikes, Tracy L Dalton, Beverly Metchock, Angela M Starks, Delaina P Hooks, Lauren S Cowan, Bonnie B Plikaytis, and James E Posey Antimicrobial agents and chemotherapy 2011 May 55(5) 2032-41 |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 15, 2021
- Content source: